Schilthuizen, C.

polymorphism patient myeloma treatment genotype therapy survival toxicity study high-dose therapy drug-metabolizing enzymes enzyme effect trial association difference response cyp 3a genotype chemotherapeutic agents agent outcome phase i metabolism center metabolism phase blood influence netherland chemotherapy hematology high-dose event-free event-free survival inter-study differences variation department →g polymorphisms treatment failure nucleotide polymorphisms myeloma patients erasmu cyp 3a cancer gstt 1 cancer chemotherapy table drug-metabolizing rotterdam utrecht analysis haematologica gstp 1 polymorphism univariate analysis event-free p values ≤0.01 myeloma b 75 mdr 1 gene mrc vii trial statistics-hovon data center antibiotic antitumor agents van der werf gstp 1 genotype sonneveld mdr 1 genes gstm 1 polymorphisms editor table 1. van der heiden patients ≤65 years phase ii metabolism result van marwijk kooy kaplanmeier survival estimates phase 2 metabolism cyp 3a gg chemotherapeutic protocol van rooyen protein expression utrecht university shaughnessy j wild-type allele